Nomura Holdings Inc. Boosts Stock Position in Omnicell, Inc. (NASDAQ:OMCL)

Nomura Holdings Inc. boosted its position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 85.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 106,463 shares of the company's stock after acquiring an additional 48,906 shares during the quarter. Nomura Holdings Inc. owned 0.23% of Omnicell worth $4,740,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Smartleaf Asset Management LLC increased its stake in Omnicell by 51.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock worth $35,000 after acquiring an additional 273 shares during the last quarter. Johnson Financial Group Inc. purchased a new stake in Omnicell during the 4th quarter valued at $37,000. Van ECK Associates Corp lifted its position in Omnicell by 47.0% in the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company's stock worth $44,000 after buying an additional 315 shares during the last quarter. Headlands Technologies LLC purchased a new position in Omnicell during the fourth quarter worth $53,000. Finally, First Horizon Advisors Inc. increased its position in Omnicell by 36.3% during the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock valued at $59,000 after acquiring an additional 355 shares during the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on OMCL shares. JPMorgan Chase & Co. cut their price objective on Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research report on Thursday, March 20th. Wells Fargo & Company upgraded Omnicell from an "equal weight" rating to an "overweight" rating and raised their price target for the company from $31.00 to $35.00 in a research note on Wednesday, May 14th. Benchmark dropped their target price on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Finally, StockNews.com raised shares of Omnicell from a "hold" rating to a "buy" rating in a research report on Tuesday. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, Omnicell presently has an average rating of "Moderate Buy" and a consensus price target of $46.50.

Omnicell Stock Down 3.1%

Shares of NASDAQ:OMCL traded down $0.90 during trading on Wednesday, reaching $27.89. The stock had a trading volume of 80,069 shares, compared to its average volume of 558,180. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $1.31 billion, a P/E ratio of 103.61, a PEG ratio of 7.53 and a beta of 0.78. The firm's 50-day simple moving average is $31.23 and its 200 day simple moving average is $39.18. Omnicell, Inc. has a one year low of $22.66 and a one year high of $55.75.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.16 by $0.10. Omnicell had a return on equity of 3.82% and a net margin of 1.13%. The business had revenue of $269.67 million for the quarter, compared to the consensus estimate of $260.18 million. During the same period in the prior year, the firm posted $0.03 earnings per share. The business's quarterly revenue was up 9.5% on a year-over-year basis. As a group, research analysts expect that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.